SAGE Therapeutics (SAGE) Misses Q3 EPS by 21c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.63), $0.21 worse than the analyst estimate of ($2.42).

Guidance:

• Based on its current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities as of September 30, 2018 will enable Sage to fund its operating expenses and capital expenditure requirements into 2020.
• Sage expects that its operating expenses will increase year-over-year in 2018 to support continued pipeline advancement, including ongoing Phase 3 development of SAGE-217, and potential commercialization of ZULRESSO in PPD, if approved

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Hertz cuts guidance, announces notes and stock offerings, shares sink